2018 ASCO Annual Meeting
The Annual Meeting brings together more than 32,000 oncology professionals from around the world to discuss the highlights of the latest cancer care treatments, new therapies, and ongoing controversies in the field, via informative and scientific sessions.
Dr. Joseph Mikhael, Chief Medical Officer from the International Myeloma Foundation, presents in the following video an overview of the top multiple myeloma research updates presented at ASCO 2018.
Congratulations to the Recipient of the Jointly Funded 2017 Myeloma Canada and Canadian Research Society Research Grant
By analyzing protein from drug-sensitive and drug-resistant myeloma cells, Dr. Chang and his team have discovered a novel protein called pMARCKS (phosphorylated myristoylated alanine-rich C-kinase substrate) that is highly expressed in drug-resistant myeloma cells.
A Second Phase III Study Shows That Carfilzomib (Kyprolis®) Significantly Improves Overall Survival in Patients with Relapsed Multiple Myeloma
August 11, 2017